Broadcast Date: April 14, 2019
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

The potential that gene-editing technology possesses is immense. Due to its ease of use and high efficiency, the CRISPR-Cas9 system is rapidly becoming the prevalent system for the genetic manipulation of cells, animal models, and plants. Yet, as with any new technological advance, improvements can be made to streamline the development process. As such, Cas-CLOVER™ is a novel gene-editing technology, which differs from traditional single-guided Cas9 and dual-guided Cas9-nickase methods, as it is a truly dimeric system. Cas-CLOVER demonstrates high fidelity with no detectable off-targets while maintaining robust editing efficiency.

In this GEN webinar, we will hear from scientific experts about the design and implementation considerations for Cas-CLOVER, as well as validation data for the use of this gene-editing system in human and CHO cells, as well as yeast and plants. Additionally, our panelists will detail the use of Cas-CLOVER in the generation of healthy donor-derived, allogeneic CAR-T cells. Finally, our presenters will show how this next generation of gene-edited CAR-T cells will overcome known challenges with manufacturing consistency and product variability, as well as meet patient demand that is typically encountered in patient-derived, autologous CAR-T.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

 

Produced with support from:

Hera Demeetra Logo

 

 

Tseten Jamling

Tseten Jamling, PhD
Vice President,
R&D and Gene Editing
Hera BioLabs

Maximillian Richter

Maximilian Richter, PhD
Senior Scientist,
Immuno-Oncology
Poseida Therapeutics